Skip to main navigation
Fennec Pharmaceuticals
  • Our Product
  • Investors

    Investor Relations

    • Investor Relations
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources

You are here: Home / Investors

    Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    • Read more about Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

    • Read more about Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

    Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

    • Read more about Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

    Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

    • Read more about Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

    Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

    • Read more about Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

    Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

    • Read more about Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

    Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

    • Read more about Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

    Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

    • Read more about Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

    Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

    • Read more about Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

    Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

    • Read more about Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

    Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page Next ›
    • Last page Last »
    Subscribe to

    Investor Tools

    • Print Page
    • Email Alerts
    • Contact IR
    • RSS Feeds

    Investor Relations

    • Investor Relations
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources
    Copyright © 2026 Fennec Pharmaceuticals
    Scroll to top